SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced Otello Stampacchia, Ph.D., of Omega Funds, resigned from the company’s Board of Directors. Dr. Stampacchia has served as a director of the company since January 2018, and Omega Funds was the founding seed investor of Gossamer.
“The support and resources we received from Otello and Omega were critical to launching Gossamer in January 2018,” said Faheem Hasnain, Chairman of Gossamer. “We wish Otello well as he focuses on his other endeavors.”
“Gossamer is an incredible organization with a bright future,” said Dr. Stampacchia. “Omega looks forward to continuing to support the team as it develops its important drugs for patients.”
“As we continue to advance our pipeline and mission to help better the lives of patients, we are tremendously grateful to Otello for his contributions to building Gossamer,” said Sheila Gujrathi, M.D., Chief Executive Officer of Gossamer Bio.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology. Its goal is to be an industry leader in each of these therapeutic areas and to enhance and extend the lives of patients suffering from such diseases.